For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Immune Modulator

Thymosin Alpha-1

Also known as: Thymalfasin (trade name Zadaxin)

Thymosin Alpha-1 (Ta1) is a 28-amino-acid thymic peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) approved as Zadaxin in 35+ countries for chronic hepatitis B/C and as an immune adjuvant. It is NOT FDA-approved in the US.

Where to buy · live market data

Who's worth your money for Thymosin Alpha-1

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 31 scored sellers

$6.40/mg

$63.99 · 10mg · 99.7% purity

6 COAs
Buy code MERIT · 10% off

Best value after code

$0.06/mg effective with 15% code

$0.07/mg

$0.65 · 10mg · 99.2% purity

2 COAs
Buy code MERIT · 15% off

Most tested

21 independent COAs on file

$4.80/mg

$48.00 · 10mg · 99.6% purity

Average price

$8.83/mg

Sellers

71

45-day trend

-10.7%

59 of 71 sellers have a current price· 20 stale hidden· 8 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Thymosin Alpha-1

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Thymosin Alpha-1

CAS

62304-98-7

Molecular formula

C129H215N33O55

Sequence

SDAAVDTSSEITTKDLKEKKEVVEEAEN

Typical dose range

1.6 mg subcutaneous 2–3x/week (clinical standard); research protocols range 1.6–6.4 mg per dose

Half-life

~2–3 hours (subcutaneous; elimination t½ <3 h confirmed by PK study)

Independent evidence

COAs for Thymosin Alpha-1

124 third-party tests across 33 vendors. Each card links to the full report.

All 124 COAs for Thymosin Alpha-1 →
Measured purity 98.9%–100.0% across 93 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.39 %
Jul 2026
Horizon Analytical

For

Thymosin Alpha-1

by Blank Peptides· batch DPS-8269267

Aggregated · 3rd-party listing
99.47 %
Jul 2026
ILS Labs Strong

For

Thymosin Alpha-1

by NG Peptide· batch TA1-05

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

Thymosin Alpha-1

by OROS Research· batch OR-LPTA5-626-B2

Aggregated · 3rd-party listing
99.65 %
Jun 2026
Janoshik Analytical Limited

For

Thymosin Alpha-1

by EZ Peptides· batch EZP-TA11006052026-04

Aggregated · 3rd-party listing
99.85 %
Jun 2026
Freedom Diagnostics Moderate

For

Thymosin Alpha-1

by Modern Research Peptides· batch 982444TU

Aggregated · 3rd-party listing
99.56 %
Jun 2026
Janoshik Analytical Limited

For

Thymosin Alpha-1

by Verified Peptides· batch TA05260910H

Aggregated · 3rd-party listing
99.61 %
May 2026
Freedom Diagnostics Moderate

For

Thymosin Alpha-1

by Blank Peptides· batch THYMA10-052026-7

Aggregated · 3rd-party listing
100.00 %
May 2026
Prime Analytical Laboratories, LLC

For

Thymosin Alpha-1

by Soma Peptides· batch TAXV042603

Aggregated · 3rd-party listing
99.57 %
May 2026
Janoshik Analytical Limited · HPLC

For

Thymosin Alpha-1

by Skye Peptides· batch TA126-10-001

Aggregated · 3rd-party listing
99.68 %
May 2026
Freedom Diagnostics Moderate

For

Thymosin Alpha-1

by Real Peptides· batch Black Cap

Aggregated · 3rd-party listing
99.32 %
Apr 2026
Horizon Analytical

For

Thymosin Alpha-1

by Pepsgpt· batch P-1947064-P

Aggregated · 3rd-party listing
98.89 %
Apr 2026
ILS Labs Strong

For

Thymosin Alpha-1

by Riptide Wellness· batch RWTA1-10-1003

✓ Vendor-published
99.98 %
Apr 2026
Kovera Labs

For

Thymosin alpha-1

by Ion Peptide· batch TA110-04202026

COA on file
Aggregated · 3rd-party listing
99.58 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

Thymosin Alpha-1

by Peptide Supply Co.· batch TA1004132026

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

Thymosin Alpha-1

by OROS Research· batch OR-LPTA5-326-B1

Aggregated · 3rd-party listing
99.81 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Thymosin

by Verified Peptides· batch cmojb57q300trkirxximley58

Aggregated · 3rd-party listing
99.91 %
Apr 2026
Biogenica Labs · HPLC

For

Thymosin Alpha-1

by Amino Club· batch THA0001

Aggregated · 3rd-party listing
99.97 %
Mar 2026
Kovera Labs

For

Thymosin alpha-1

by Ion Peptide· batch TA110-03232026

✓ Vendor-published
99.97 %
Mar 2026
Kovera Labs

For

Thymosin alpha-1

by Ion Peptide· batch TA110-03232026

COA on file
Aggregated · 3rd-party listing
99.92 %
Mar 2026
Freedom Diagnostics Moderate

For

Thymosin Alpha-1

by Modern Research Peptides· batch MKUST5WC3526

Aggregated · 3rd-party listing
99.75 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

Thymosin Alpha-1

by Profound Aminos· batch cmojb89io01hzkirx1zv5axqw

Aggregated · 3rd-party listing
99.39 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

Thymosin Alpha-1

by Verified Peptides· batch TA032608106

Aggregated · 3rd-party listing
99.95 %
Feb 2026
Kovera Labs · HPLC

For

Thymosin Alpha-1

by Peptide Partners· batch TA202602

✓ Vendor-published
99.95 %
Feb 2026
Kovera Labs

For

Thymosin alpha-1

by Peptide Partners· batch TA202602

COA on file
Research depth

20 citations indexed for Thymosin Alpha-1

All research on Thymosin Alpha-1 →

Study · 2026

Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells

Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (ABs) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of co-administered or second-line immunotherapies.

Study · 2026

A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1

To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.

rct · 2026

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC).

review · 2025

Aging and Thymosin Alpha-1

Aging is characterized by immune decline, mainly due to thymic involution-the age-related shrinkage of the thymus gland. This leads to reduced T-cell production, chronic inflammation, and increased susceptibility to age-related diseases.

Study · 2025

The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets

Background The immune-balancing role of thymosin alpha 1 (Tα1) is well-recognized in contexts of immune dysregulation. Within the anti-tumor context, Tα1 demonstrated to act as an immune-enhancer, with potential roles in immunotherapy-based treatments.

meta-analysis · 2025

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis

Background Immune and inflammatory disorders are part of the complex pathophysiological processes that exacerbate severe acute pancreatitis (SAP) and subsequent infection.